Proton Beam Re-Irradiation in Thoracic Cancers



Status:Completed
Conditions:Lung Cancer, Lung Cancer, Lung Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:11/22/2018
Start Date:September 9, 2014
End Date:September 7, 2017

Use our guide to learn which trials are right for you!

Definitive Re-irradiation With Proton Beam Radiotherapy for Patients With Recurrent Thoracic Cancers

This pilot clinical trial studies proton beam radiation therapy in treating patients with
thoracic cancer that has come back and have received prior radiation therapy. Proton beam
radiation therapy uses high energy protons to kill tumor cells and may cause less damage to
normal tissue.

PRIMARY OBJECTIVES:

I. To assess the grade 3 toxicity associated with thoracic re-irradiation with proton
therapy, with prospectively applied normal organ radiation dose limits.

SECONDARY OBJECTIVES:

I. To assess the efficacy of thoracic re-irradiation with proton therapy.

OUTLINE:

Patients undergo proton beam radiation therapy per standard of care.

After completion of study treatment, patients are followed up at 3 months.

Inclusion Criteria:

- Women of child-bearing age must have a negative pregnancy test

- Patients must have received prior radiation treatment to the chest; records of prior
radiation treatment must be available

- Patients must have received prior chest radiation at least 3 months prior to
enrollment in this trial; radiation treatment to other body sites not overlapping with
current radiation fields are allowed within the 3 months period (example, brain
radiation is allowed)

- Patients must have a prior diagnosis of cancer inside the thoracic cavity; both
primary thoracic malignancies (such as lung cancer) as well as metastatic lesions
(such as metastatic breast cancer or colorectal cancer to the lungs) are allowed;
patient must have pathologic confirmation of the recurrent thoracic tumor, or have an
enlarging thoracic mass (as seen on two computed tomography [CT] scans at least 6
weeks apart, with either a > 25% or > 5 mm increase in longest dimension)

- Patients must have a life expectancy of > 6 months

- Patients must have measurable disease to be treated with proton radiation (minimum
tumor dimension at least 10 mm on CT imaging)

- Patients should have either non-metastatic cancer of the thorax, or metastatic cancer
to the thorax and candidate for definitive radiation dose to the thoracic tumor (not
palliative intent), tumor radiation dose to at least BED2Gy 60 Gy

- Patients must be able to receive proton radiation treatment

- All stages of cancer are eligible

- There are no limits on prior therapy; patients are allowed to have prior chemotherapy
and surgery; patients are allowed to have concurrent chemotherapy with radiation
treatment; patients are allowed to have chemotherapy or surgery after radiation
treatment

- Patients are allowed to be on another study concurrent with this protocol

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have never received radiation to the chest

- Patients who received radiation to the chest within the past 3 months (in a region
that overlaps with current radiation fields)

- Patients with life expectancy < 6 months

- Pregnant women

- Patients unable to provide informed consent

- Prisoners
We found this trial at
2
sites
Seattle, Washington 98133
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
206-667-4584
Principal Investigator: Jing Zeng
Phone: 206-598-4100
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
?
mi
from
Seattle, WA
Click here to add this to my saved trials